Abstract: The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolated muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.

Abstract: The present invention develops a novel method for controlling mosquito populations. Culicinae mosquitoes carrying one or more loci of transformant Tra-2 RNAi constructs which target to mosquito Transformer-2 locus in respective or none respective Culicinae mosquitoes. Tra-2 sequences used to assemble Tra-2 RNAi recombinant constructs are Tra-2 gene sequences of Culicinae mosquitoes and can be derived from endogenous or exogenous sequences. The Tra-2 RNAi expression is conditional, wherein the expression causing a knockdown effect into the endogenous Tra-2 gene results in mortality of X (m) chromosome bearing sperms and produces maleness mosquito population in the nature environmental of the species.

Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.

Abstract: Rich tooling is provided for REST application development that integrates the exploration of a REST API, modeling of data types and the REST API, and the generation of artifacts using the modeled REST API and data types.

Abstract: The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.

Abstract: The present invention relates to methods for preventing and treating chronic kidney disease (CKD).

Abstract: The invention refers to an oligonucleotide consisting of 10 to 20 nucleotides of selected regions of the TGF-beta1, TGF-beta2 or TGF-beta3 nucleic acid sequence, which comprises modified nucleotides such as LNA, ENA, polyalkylene oxide-, 2?-fluoro, 2?-O-methoxy and/or 2?-O-methyl modified nucleotides. The selected regions are preferably the region of nucleic acid no. 1380 to 1510, no. 1660 to 1680, no. 2390 to 2410, or no. 2740 to 2810 of the TGF-beta2 nucleic acid sequence of SEQ ID NO. 1, specific regions of the TGF-beta1 nucleic acid sequence of SEQ ID NO. 149, or specific regions of the TGF-beta3 nucleic acid sequence of SEQ ID No. 267. The invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used in the prevention and/or treatment of a malignant and/or benign tumor, an immunologic disease, fibrosis, glaucoma, etc.

Abstract: Monomeric and multimeric aptamers are provided. Also provided are pharmaceutical compositions which comprise same and methods of using same.

Abstract: A recombinant nucleic acid comprising an aptamer that binds CD4 and an RNAi sequence that silences the expression of ROR?2 is described herein. Pharmaceutical compositions comprising the recombinant nucleic acid, particularly topical compositions are also described. Methods of treating inflammatory disease using the pharmaceutical composition are also described.

Abstract: Described herein are compositions comprising a first aptamer, second aptamer and a target that are capable of forming a ternary complex, and wherein the first aptamer and the second aptamer comprise C-5 pyrimidine modification schemes that are different, and methods of making and using such compositions.

Abstract: The current invention reports a promoter having the nucleic acid sequence of SEQ ID NO: 02, or SEQ ID NO: 03, or SEQ ID NO: 04, or SEQ ID NO: 06, which is a 5? shortened SV40 promoter with reduced promoter strength especially useful for the limited expression of heterologous polypeptides or selectable markers.

Abstract: The invention provides compositions and methods for clostridial bacteria that have been engineered to produce and/or to improve efficiency of production of industrial bioproducts.

Abstract: The invention discloses a promoter which can be induced to express in acidic conditions, and relates to the field of bioengineering technology. The promoters of the invention are separated from A. niger and can actuate and/or regulate the expression of the effectively connected nucleic acids in A. niger. In the invention the expression of the promoters is studied in A. niger, and it is indicated that some promoters show weak expression, and some show strong activity. The invention provides an effective method and new thought for organic acids production by fungi or other products produced by fermentation under acidic conditions.

Abstract: The present invention relates to genetically modified host cells, in particular yeast cells, comprising at least one isolated polynucleotide encoding a Killer Expression protease (Kex2p) or a fragment and/or variant thereof which has at least one Kex2p functional activity and at least one isolated polynucleotide encoding a Protein Disulfide-Isomerase (Pdi1) or a fragment and/or variant thereof which has at least one Pdi functional activity.

Abstract: A variety of methods and compostions are provided, including methods and compositions for targeted modification of a specific target site in a cell or organism, methods for integrating polynucleotides of interest, methods to assess promoter activity, directly select transformed organisms, minimize or eliminate expression resulting from random integration into the genome of an organism, such as a plant, remove polynucleotides of interest, combine multiple transfer cassettes, invert or excize a polynucleotide, silence a gene, and identify and/or characterize transcriptional regulating regions. The methods involve the introduction of a cell proliferation factor and a double-strand break-inducing enzyme into an organism.

Abstract: The present invention relates to plants of the Compositae family exhibiting a reversible genic male sterility trait, characterized in that the genic male sterility is caused by a reduction or complete absence of endogenous jasmonic acid production, resulting from interference with one or more target genes involved in endogenous jasmonic acid production, selected from the group consisting of lipoxygenase, allene oxide synthase, allene oxide cyclase and 12-oxo-phytodienoic acid-10, 11-reductase, or their functional homologues.

Abstract: Disclosed is a glyphosate-tolerant gene. The nucleotide sequence of the gene is SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5, and a mutant form of the gene that maintains the glyphosate-tolerant activity. The amino acid sequence of a protein encoded by the gene is respectively SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, and a mutant form of amino acids in a conserved region 1 of positions 280 to 294 and in a conserved region 2 of positions 416 to 433. Also disclosed is the use of the gene and the mutant form thereof in the production of a glyphosate-resistant/tolerant plant.

Abstract: The present invention relates to compositions and methods, in particular to methods based on systemic injection of rAAV, for delivering genes to cells of the central nervous system in mammals, such as brain neurons or glial cells, and in particular to motor neurons or glial cells of the spinal cord The invention also relates to methods of treating motor neuron disorders in mammals by expression of therapeutic genes. The invention stems from the unexpected discovery that peripheral injection of AAV vectors leads to a bypass of the blood brain barrier and a massive infection of motor neurons. The invention may be used in any mammal, including human subjects.

Abstract: The invention relates to a bioreactor for methanizing biomass, a biogas plant having a plurality of such bioreactors, and a method for operating such a bioreactor. Because the elongated reactor vessel includes both a loading gate and an unloading gate that are arranged at opposite ends of the elongated reactor vessel, it is possible to remove consumed biomass, which is harmless in terms of epidemiologic hygiene and plant hygiene due to thermophilic process control during the fermentation, from the reactor vessel through the unloading gate and to transfer this consumed biomass directly to the composting process. The bioreactor thus has a “clean” unloading gate and an “unclean” loading gate.

Abstract: A fermentation process for the production of ethanol from natural sources, such as corn, comprising introducing a fermentable sugar, an inoculant, and a stabilized chlorine dioxide into a fermentation system is disclosed. The stabilized chlorine dioxide is added preventatively to the fermentation system, at concentrations in the fermentation system of acetic acid no greater than 0.30% (weight/volume) and lactic acid no greater than 0.60% (weight/volume). The stabilized chlorine dioxide is added in an amount effective to substantially prevent growth of bacteria.

Abstract: The present invention provides recombinant microorganisms comprising an isobutanol producing metabolic pathway and methods of using said recombinant microorganisms to produce isobutanol. In various aspects of the invention, the recombinant microorganisms may comprise a modification resulting in the reduction of pyruvate decarboxylase and/or glycerol-3-phosphate dehydrogenase activity. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.

Abstract: A process for the preparation of butanediol includes providing an aqueous medium comprising magnesium succinate by fermentation of a carbohydrate source, in the presence of a magnesium base. The aqueous medium is processed wherein the magnesium succinate is treated with a monovalent base, prior to or after a crystallization step, to provide a magnesium base and an aqueous solution comprising a monovalent succinate salt. The concentration of the monovalent succinate salt is adusted to between 10 and 35 wt. %. The aqueous solution is subjected to water-splitting electrodialysis, to produce a first solution comprising monovalent base and a second solution comprising succinic acid and monovalent succinate salt, the electrodialysis causing conversion the monovalent succinate salt into succinic acid of 40 to 95 mole % calculated on a total molar amount of succinic acid and succinate present in solution. The second solution is separated into succinic acid and the monovalent succinate salt by crystallization.

Abstract: The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desatorase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids.

Abstract: A process for producing on an industrial scale the oxidized coenzyme Q10, includes culturing a reduced coenzyme Q10-producing microorganism selected from the group consisting of the genus Rhodobacter, the genus Saitoella, the genus Schizosaccharomyces and the genus Trichosporon, to obtain microbial cells containing reduced coenzyme Q10 at a ratio of not less than 70 mole % among the entire coenzymes Q10; and one of: (a) oxidizing thus-obtained reduced coenzyme Q10 to oxidized coenzyme Q10 and then extracting the oxidized coenzyme Q10 by an organic solvent; or (b) extracting reduced coenzyme Q10 by an organic solvent and oxidizing the extracted reduced coenzyme Q10 to oxidized coenzyme Q10.

Abstract: The present invention relates to an isolated DNA molecule encoding a fagopyritol synthase. A method for producing a fagopyritol, an insulin mediator, an insulin mediator analog, an insulin mediator homolog, or an insulin mediator inhibitor is also described. The method includes providing a fagopyritol synthase, providing a substrate comprising a galactosyl donor and a galactosyl acceptor, and combining the fagopyritol synthase with the substrate under conditions effective produce a fagopyritol, an insulin mediator, an insulin mediator analog, an insulin mediator homolog, or an insulin mediator inhibitor.

Abstract: Herein is reported a method for producing a polypeptide comprising the step of incubating (resuspended) prokaryotic cells in a solution comprising about 10 mM to about 95 mM Tris-HCl and about 2 mM to about 6 mM EDTA at a pH value of about 7 to about 10 for about 15 min to about 6 h at about 25° C.

Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.

Abstract: The present invention relates to methods of recombinantly producing a natively secreted polypeptide, the method comprising the steps of providing a microorganism host cell comprising an exogenous polynucleotide encoding a natively secreted polypeptide without a translationally fused signal peptide; cultivating the microorganism host cell under conditions conducive to the expression of the polypeptide and, optionally, recovering the polypeptide, as well as microorganisms, certain polynucleotides, expression constructs and protease substitution variants.

Abstract: Provided are a method of producing minor ginsenosides using a ginsenoside glycosidase protein derived from a Microbacterium sp. (Microbacterium testaceum) microorganism, and a composition including the protein for conversion into minor ginsenosides. The ginsenoside glycosidase exhibits very excellent activity of specifically hydrolyzing a sugar at the C-6 position of ginsenoside to convert the ginsenoside into in-vivo absorbable minor ginsenoside, thereby being very usefully applied to mass-production of ginsenoside.

Abstract: The present specification discloses methods of detecting a pathogen of interest, components useful in carrying out these methods, including a pre-enrichment media, and enrichment media and a detection solution and kits thereof.

Abstract: The present invention relates to the use, notably cosmetic and/or therapeutic, of the YKL-40 protein belonging to the family of chitinase-type proteins, of polypeptides derived from this protein or analogs thereof of a nucleic acid sequence encoding such a polypeptide or of an agent that modulates the activity or expression of such a polypeptide notably for stimulation of terminal epithelial differentiation.

Abstract: This invention provides methods for treating diseases associated with elevated p38 mitogen-activated protein kinase activity. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same.

Abstract: A complex mixture is analyzed for multiple nucleic acid sequences (e.g., DNA or RNA sequences) simultaneously by target specific multiplex amplification followed by single molecule detection of amplicons by Atomic Force Microscopy (AFM). The presence or absence of target nucleic acids can be determined from the presence or absence of specific amplicons for those nucleic acids. In addition, quantification of target nucleic acids in the complex mixture is achieved by determination of the numbers of amplicons.

Abstract: Devices including a composition for preserving and processing cell-free nucleic acids located within a blood sample and methods of using the same are disclosed, wherein a blood sample containing cell-free nucleic acids is treated to reduce both blood cell lysis and nuclease activity within the blood sample. The device may include a direct blood draw tube comprising a composition formulated for stabilizing cell-free nucleic acids within a blood sample including one or more formaldehyde releaser preservative agents, ethylenediaminetetraacetic acid (EDTA), one or more solvents, and formaldehyde. The composition is free of separately added formaldehyde but contains the formaldehyde as a result of the one or more formaldehyde releaser preservative agents. The treatment of the sample aids in increasing the amount of cell-free nucleic acids that can be identified and tested while maintaining the structure and integrity of the nucleic acids.

Abstract: A fluid identification system comprising a plurality of particles, each particle encapsulating therein at least one tracer material having an identifiable DNA, the at least one tracer material being encapsulated by an encapsulation material, wherein the particles are adapted to retain the at least one tracer material in an encapsulated form after exposure of the particles to a temperature of at least 75° C. and/or a pressure of at least 1000 psi (6.9×106 N/m2).

Abstract: A category of ?PNA miniprobes and chimeric ?PNA probes is especially useful for detecting RNA and telomeric DNA in a cell sample. In particular, the probes can be used to deliver fluorescent dyes to the telomeres, allowing direct visualization of telomeres in cells.

Abstract: Provided are methods for identifying the presence or absence of a chromosome abnormality by which a cell-free sample nucleic acid from a subject is analyzed. In certain embodiments, provided are methods for identifying the presence or absence of a fetal chromosome abnormality in a nucleic acid from cell-free maternal blood.

Abstract: A method for the amplification of nucleic acids, in which nanoparticles in a reaction volume transfer heat to their environment through excitation. The method comprises a step of providing nanoparticles with the nucleic acids in a reaction volume and one or more heating steps. In at least one of the heating steps, the heating is achieved at least partially through the excitation of the nanoparticles. The interval of the excitation is chose to be shorter or equal to a critical excitation time.

Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

Abstract: The invention relate to systems and methods for sequencing polynucleotides, as well as detecting reactions and binding events involving other biological molecules. The systems and methods may employ chamber-free devices and nanosensors to detect or characterize such reactions in high-throughput. Because the system in many embodiments is reusable, the system can be subject to more sophisticated and improved engineering, as compared to single use devices.

Abstract: A method for nucleic acid sequencing includes (a) disposing a plurality of template polynucleotide strands in a plurality of defined spaces disposed on a sensor array, at least some of the template polynucleotide strands comprising a test or control sequence; (b) exposing a plurality of the template polynucleotide strands in the defined spaces to a series of flows of nucleotide species flowed according to a predetermined ordering; and (c) determining sequence information for a plurality of the template polynucleotide strands in the defined spaces based on the flows of nucleotide species to generate a plurality of sequencing reads corresponding to the template polynucleotide strands, wherein the test or control sequence comprises a sequence determined by identifying, using a variant caller, loci with systematic errors present in a plurality of sequencing runs included in a training set of sequencing runs.

Abstract: The present disclosure relates to the field of molecular biology and more specifically to methods for capturing, amplifying and sequencing target polynucleotides on a solid surface.

Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD3CD4 positive T lymphocytes of a mammal, wherein the method comprises analyzing the bisulfite convertibility of at least one CpG position in the CD3+CD4+ T helper cell specific non-methylated bisulfite convertible region according to SEQ ID No. 1, wherein a bisulfite convertibility of at least one CpG position to at least 90%, preferably to at least 91% and more preferably to at least 92% and most preferred to at least 95% in the sample is indicative for a CD4+ T-lymphocyte cell, in particular a CD3+CD4+ T-lymphocyte cell. The present invention further relates to analyzing the bisulfite convertibility of at least one CpG position in the genes FLJ00060, FLJ38379, PPP6C, CD226, ZBTB7B and TNFAIP8 that are capable of positively identifying CD4 expressing cells in whole blood and segregate between CD4 and CD8 positive CD3 positive cells.

Abstract: Compositions and methods for the detection and treatment of T1D are provided.

Abstract: The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.

Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for prostate cancer.

Abstract: A procedure and an apparatus are described for identifying individuals at risk of pulmonary tumour and/or for diagnosing a pulmonary tumour using the study of levels of expression of miRNA in the blood or another biological fluid. Also described are a method and a compound for reducing or eliminating a risk of pulmonary tumour by rebalancing the miRNAs that are underexpressed or overexpressed.

Abstract: Methods for differentiating squamous cell carcinoma from pseudoepitheliomatous hyperplasia in a biological sample using KRT9 and C15orf48, methods of using differentially expressed genes as prognostic markers for squamous cell carcinoma, methods of using molecular pathways as targets for the treatment of squamous cell carcinoma, and diagnostic kits therefor.

Abstract: The present invention relates to HPV-positive as well as HPV-negative screening platforms that are highly serum-dependent, for use as HNSCC models. These HNSCC models die reproducibly in serum-deprived conditions and the introduction of driver mutations (or increased levels of the WT gene) confers enhanced cell survival and proliferation under serum deprivation. These platforms have the major advantages of allowing functional screening of mutations in relevant HNSCC models (HPV-positive and HPV-negative). In addition to oncogene screening, this model can also be used in drug discovery. Specifically, cells expressing mutations that confer increased survival can then be screened against panels of therapeutic agents to determine if the mutation(s) can predict the optimal treatment for patients whose tumors harbor the mutation(s).